Aprea Therapeutics, Inc.

APRE

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.6403

+$0.0075 · +1.19%

Aug 21, 4:00 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

37/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Fair Value

Momentum

Weakening

Sentiment

Bullish

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Oren Gilad
Listed since: Oct 3, 2019
Employees: 8

Market position

Day range

Current $0.6403

$0.623$0.6697

52-week range

Current $0.6403

$0.548$1.69

Open: $0.6565
Previous close: $0.6328
Volume: 14.69K; 0.12× average
Average volume: 122.74K; Average daily volume
Market cap: 7.93M USD
Beta: 1.59; Market reference 1
50-day average: $0.6977; -8.23% below average
200-day average: $0.839; -23.68% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: -9.02M USD
P/E (TTM): -0.5×
P/B (TTM): 0.89×
P/S (TTM): 0×
EV / EBITDA: 0.72×
Earnings yield: -225.90%
Free cash flow yield: -231.19%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -101.27%
Return on assets: -79.08%
Return on invested capital: -100.49%

Financial health

Debt / equity: 0×
Current ratio: 5.63×

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

8 ratings

Strong buy00%

Buy450%

Hold225%

Sell225%

Strong sell00%

APRE news

globenewswire.comAug 12, 2026

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances

Read source

prnewswire.comAug 3, 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through

Read source

globenewswire.comJul 30, 2026

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with APR-1051…

Read source

globenewswire.comJun 1, 2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohorts Patient expansion…

Read source